Anti-HDV seroprevalence in patients with decompensated liver cirrhosis due to hepatitis B


  • Nergiz Ekmen Department of Gastroenterology, Faculty of Medicine, Gazi University, Ankara, Turkey
  • Sami Cifci Clinic of Gastroenterology, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey


Anti-HDV, hepatitis B, hepatitis D, liver cirrhosis


Aim: Hepatitis B (HBV) and Hepatitis D (HDV) viruses are among the two important causes of end-stage liver disease today. In this study, we aimed to increase HDV awareness in people infected with HBV by examining the prevalence of HDV in patients with end-stage liver disease due to HBV and who were evaluated for liver transplantation.
Materials and Methods: The study was designed as a retrospective single-center and cross-sectional. Patients with HBV decompensated liver cirrhosis were divided into two groups as anti-HDV positive and negative. Child-turcott pugh (CTP), Model for End-Stage Liver Disease (MELD) score, complications of liver cirrhosis, viral hepatitis serology, and platelet count variables were statistically compared between the groups.
Results: A total of 147 patients with decompensated liver cirrhosis due to HBV were included in the study. Anti-HDV positivity was detected in 46 (31.3%) patients, and anti-HDV negative in 101 (68.7%) patients. The mean age of HDV positive patients (48.39±9.20) was statistically significantly lower than HDV negative (54.37±7.80) patients (p<0.001). Although MELD and CTP scores were slightly higher in the anti-HDV negative group, there was no statistically significant difference between the groups in terms of both scores (p=0.401; p=0.782, respectively). The platelet count was found to be significantly lower in the anti-HDV positive group than in the anti-HDV negative group (p=0.008).
Conclusion: The rate of encountering HDV in end-stage liver disease due to HBV was found to be quite high. HDV is an important factor in the development of end-stage liver disease in HBV-infected individuals, especially at an early age, and taking precautions for this is of great importance.




How to Cite

Ekmen, N., & Cifci, S. (2021). Anti-HDV seroprevalence in patients with decompensated liver cirrhosis due to hepatitis B. Annals of Medical Research, 28(9), 1771–1774. Retrieved from



Original Articles

Similar Articles

You may also start an advanced similarity search for this article.